Publications

Journal Article
Review
Epublish 12 citations
Electronic publication date
June 25, 2024

View on Pubmed.gov 38915399 | View on doi.org 10.3389/fimmu.2...

Role of gut microbiota in regulating immune checkpoint inhibitor therapy for glioblastoma.

Search for publications in this journal Front Immunol

  • Hao Zhang

    Search for this expert
    1
  • Ying Hong

    Search for this expert
    1
  • Tingting Wu

    Search for this expert
    2
  • Eyi Ben

    Search for this expert
    3
  • Shuai Li

    Search for this expert
    4
  • Liu Hu

    Search for this expert
    1
  • Tao Xie 1

Abstract

Glioblastoma (GBM) is a highly malignant, invasive, and poorly prognosed brain tumor. Unfortunately, active comprehensive treatment does not significantly prolong patient survival. With the deepening of research, it has been found that gut microbiota plays a certain role in GBM, and can directly or indirectly affect the efficacy of immune checkpoint inhibitors (ICIs) in various ways. (1) The metabolites produced by gut microbiota directly affect the host's immune homeostasis, and these metabolites can affect the function and distribution of immune cells, promote or inhibit inflammatory responses, affect the phenotype, angiogenesis, inflammatory response, and immune cell infiltration of GBM cells, thereby affecting the effectiveness of ICIs. (2) Some members of the gut microbiota may reverse T cell function inhibition, increase T cell anti-tumor activity, and ultimately improve the efficacy of ICIs by targeting specific immunosuppressive metabolites and cytokines. (3) Some members of the gut microbiota directly participate in the metabolic process of drugs, which can degrade, transform, or produce metabolites, affecting the effective concentration and bioavailability of drugs. Optimizing the structure of the gut microbiota may help improve the efficacy of ICIs. (4) The gut microbiota can also regulate immune cell function and inflammatory status in the brain through gut brain axis communication, indirectly affecting the progression of GBM and the therapeutic response to ICIs. (5) Given the importance of gut microbiota for ICI therapy, researchers have begun exploring the use of fecal microbiota transplantation (FMT) to transplant healthy or optimized gut microbiota to GBM patients, in order to improve their immune status and enhance their response to ICI therapy. Preliminary studies suggest that FMT may enhance the efficacy of ICI therapy in some patients. In summary, gut microbiota plays a crucial role in regulating ICIs in GBM, and with a deeper understanding of the relationship between gut microbiota and tumor immunity, it is expected to develop more precise and effective personalized ICI therapy strategies for GBM, in order to improve patient prognosis.

References

Front Immunol. 2022 Nov 17;13:1003651

Int J Mol Sci. 2018 Feb 01;19(2):

Cell Death Dis. 2024 Apr 9;15(4):254

Methods Mol Biol. 2024;2761:181-207

Cited by 12 citations (total)

Journal Article Review

Role of the TLR signaling pathway in the pathogenesis of glioblastoma multiforme with an emphasis on immunotherapy.

Electronic publication date July 29, 2025

Search for publications in this journal Biochem Biophys Rep

Seyedeh Elham Norollahi [...] Ali Akbar Samadani et al.

The most malignant brain tumor, glioblastoma multiforme (GBM), has a high mortality rate. Recently, translational elements in GBM therapy have...

Journal Article Review

Targeting gut microbiota: a potential therapeutic approach for tumor microenvironment in glioma.

Electronic publication date April 4, 2025

Search for publications in this journal Front Neurol

Fan Qi [...] Zhaoqun Feng et al.

Glioma, being one of the malignant tumors with the highest mortality rate globally, has an unclear pathogenesis, and the existing...

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

MeSH

Specialties

Substances

Copyright

Copyright © 2024 Zhang, Hong, Wu, Ben, Li, Hu and Xie.